{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:45:05Z","timestamp":1771062305979,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.seizure.2021.04.017","type":"journal-article","created":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T18:22:44Z","timestamp":1619374964000},"page":"41-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Blood concentration of levetiracetam after bolus administration in patients with status epilepticus"],"prefix":"10.1016","volume":"89","author":[{"given":"Makihiko","family":"Nagano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Tagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mio","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoshi","family":"Sugaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisamitsu","family":"Takase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamune","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Unemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2021.04.017_bib0001","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2125.2007.02931.x","article-title":"Anticonvulsant therapy for status epilepticus","volume":"63","author":"Prasad","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2021.04.017_bib0002","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(15)00042-3","article-title":"Status epilepticus in adults","volume":"14","author":"Betjemann","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2021.04.017_bib0003","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/epi.12926","article-title":"A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy","volume":"56","author":"Werhahn","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.04.017_bib0004","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.04.017_bib0005","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/14656566.2017.1323873","article-title":"Pediatric status epilepticus: improved management with new drug therapies?","volume":"18","author":"Verrotti","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.seizure.2021.04.017_bib0006","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.yebeh.2018.08.026","article-title":"Levetiracetam circulating concentrations and response in status epilepticus","volume":"88","author":"Perrenoud","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2021.04.017_bib0007","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0. National Institutes of Health (NIH)."},{"key":"10.1016\/j.seizure.2021.04.017_bib0008","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1056\/NEJM199809173391202","article-title":"A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group","volume":"339","author":"Treiman","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2021.04.017_bib0009","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.seizure.2012.01.008","article-title":"Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: a systematic review","volume":"21","author":"Zelano","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2021.04.017_bib0010","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1905795","article-title":"Randomized trial of three anticonvulsant medications for status epilepticus","volume":"381","author":"Kapur","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2021.04.017_bib0011","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.yebeh.2016.09.030","article-title":"Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus","volume":"64","author":"Brigo","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2021.04.017_bib0012","article-title":"Clinical Practice Guideline for status epilepticus 2018","year":"2018","journal-title":"Igakusyoin"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121001345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121001345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:57:54Z","timestamp":1761011874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131121001345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":12,"alternative-id":["S1059131121001345"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2021.04.017","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood concentration of levetiracetam after bolus administration in patients with status epilepticus","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2021.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}